Pharmacologist, calls for a guideline for standard quality for drugs to be formulated.

Hyderabad: The Central Drugs Laboratory and Regional Drugs Testing Laboratory are not carrying out checks to see if drugs are of standard quality (SQ) and labelling them as such. Government hospitals too do not carry out tests on sample batches of medicines supplied to them. This results in substandard drugs often being used. Dr Naveen Kumar, a senior pharmacologist, calls for a guideline for standard quality for drugs to be formulated. “This will then allow categorisation of drugs. Due to constant complaints of low quality of drugs, and the slow pace of growth of generic medicines in India, a pressure group is demanding that there must be data on standard quality drugs,” he says.

Generic drugs exported to European countries and the US have proper labelling and are constantly checked by the Food and Drug Administration, so the demand for a similar process to be set up in India is eminently reasonable. The Drugs Controller General of India has made several representations for guidelines and data of SQ drugs manufactured in India. But no data has been published by the government so far.

A senior drug control officer in TS explained, “Presently, 80 per cent of anti-retro viral drugs used worldwide to combat AIDS are from Indian pharmaceutical companies. The quality and efficacy of drugs manufactured by domestic players has helped to carve a niche in the global generic market. The problems being seen in India are from manufacturers who are not in the branded generic category. These players need to be regulated and till that is done, the issue of efficacy will be raised from time to time.”

To carry out tabulation of standard quality, the Drug Controller of India has to have sufficient manpower for checking, testing and regulating. With huge volumes being produced and the unorganized sector being involved, it is a challenge. The organised sector gets visits from inspectors from time to time, and sudden inspections are carried out only on suspicion. The SQ data will create clarity for the pharmaceutical companies and also the governing body, and benefit patients and hence there is increasing pressure that it must be formulated.

Related Posts

Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

Sarvesh Singh, Director and CEO of Telangana Lifesciences and Pharma, called on industry leaders at a CII Telangana conference to embed safety by design into manufacturing culture, deploying AI, IoT,…

CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

Amidst tariff tensions with the US, Europe has created a major opportunity for the Indian pharmaceutical industry. The CDSCO has granted approval to three Indian companies to export APIs to…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

Telangana official urges pharma sector to treat safety as a competitive edge, not a checkbox

CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

CDSCO Approves Indian Pharma Companies for EU API Exports, Opening New Growth Opportunities

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Researchers discover a compound that can boost ageing muscle repair

Researchers discover a compound that can boost ageing muscle repair

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks